PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AS
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Diversification

Asset Allocation


HROW 12.5%TMDX 12.5%REGN 12.5%AGRX 12.5%NVO 12.5%XLV 12.5%SWAV 12.5%LLY 12.5%EquityEquity
PositionCategory/SectorWeight
AGRX
Agile Therapeutics, Inc.
Healthcare

12.50%

HROW
Harrow Health, Inc.
Healthcare

12.50%

LLY
Eli Lilly and Company
Healthcare

12.50%

NVO
Novo Nordisk A/S
Healthcare

12.50%

REGN
Regeneron Pharmaceuticals, Inc.
Healthcare

12.50%

SWAV
ShockWave Medical, Inc.
Healthcare

12.50%

TMDX
TransMedics Group, Inc.
Healthcare

12.50%

XLV
Health Care Select Sector SPDR Fund
Health & Biotech Equities

12.50%

S&P 500

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AS, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Quarterly


100.00%150.00%200.00%2024FebruaryMarchAprilMayJune
225.25%
86.73%
AS
Benchmark (^GSPC)
Portfolio components

The earliest data available for this chart is May 2, 2019, corresponding to the inception date of TMDX

Returns By Period


Year-To-Date1 month6 months1 year5 years (annualized)10 years (annualized)
^GSPC
S&P 500
14.22%2.70%14.58%25.29%13.38%10.79%
AS33.98%4.15%36.19%29.49%23.34%N/A
HROW
Harrow Health, Inc.
91.79%20.07%103.22%15.98%22.79%12.06%
TMDX
TransMedics Group, Inc.
78.02%0.16%78.79%75.48%38.35%N/A
REGN
Regeneron Pharmaceuticals, Inc.
21.13%8.01%25.65%36.44%28.48%14.44%
AGRX
Agile Therapeutics, Inc.
-82.92%-11.18%-82.92%-88.15%-83.73%-66.56%
NVO
Novo Nordisk A/S
38.24%4.59%39.24%80.42%42.95%21.79%
XLV
Health Care Select Sector SPDR Fund
8.67%2.25%9.76%13.24%11.86%11.00%
SWAV
ShockWave Medical, Inc.
75.67%0.18%74.16%14.39%44.09%N/A
LLY
Eli Lilly and Company
53.23%10.24%56.59%95.44%53.99%33.07%

Monthly Returns

The table below presents the monthly returns of AS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20242.78%1.94%3.51%2.64%14.61%33.98%
20232.07%2.71%6.25%4.70%-8.96%5.01%2.19%-5.66%-5.24%-6.68%7.14%4.06%5.97%
2022-13.76%4.47%8.51%-15.34%6.34%-0.88%-0.56%10.76%1.44%6.61%1.19%3.07%8.36%
202110.86%4.16%-0.58%1.37%4.88%5.90%-0.87%10.24%-7.80%1.89%-7.46%-1.91%20.45%
20201.59%-6.73%-9.50%19.24%3.94%5.01%-0.23%10.28%-3.98%-9.33%13.79%9.93%33.73%
20198.41%9.52%-9.62%-5.12%-2.69%0.51%19.31%10.46%31.25%

Expense Ratio

AS has an expense ratio of 0.01% which is considered to be low. Below you can find the expense ratios of portfolio funds side-by-side and effortlessly compare their relative costs.


Expense ratio chart for XLV: current value at 0.12% compared with the broader market ranging from 0.00% to 2.12%.0.50%1.00%1.50%2.00%0.12%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AS is 26, suggesting that the investment has average results relative to other portfolios in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of AS is 2626
AS
The Sharpe Ratio Rank of AS is 2424Sharpe Ratio Rank
The Sortino Ratio Rank of AS is 2323Sortino Ratio Rank
The Omega Ratio Rank of AS is 2323Omega Ratio Rank
The Calmar Ratio Rank of AS is 4242Calmar Ratio Rank
The Martin Ratio Rank of AS is 2020Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

This table presents a comparison of risk-adjusted performance metrics for positions. Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


AS
Sharpe ratio
The chart of Sharpe ratio for AS, currently valued at 1.32, compared to the broader market0.002.004.001.32
Sortino ratio
The chart of Sortino ratio for AS, currently valued at 1.91, compared to the broader market-2.000.002.004.006.001.91
Omega ratio
The chart of Omega ratio for AS, currently valued at 1.23, compared to the broader market0.801.001.201.401.601.801.23
Calmar ratio
The chart of Calmar ratio for AS, currently valued at 1.40, compared to the broader market0.002.004.006.008.0010.001.40
Martin ratio
The chart of Martin ratio for AS, currently valued at 3.57, compared to the broader market0.0010.0020.0030.0040.0050.003.57
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.16, compared to the broader market0.002.004.002.16
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.06, compared to the broader market-2.000.002.004.006.003.06
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.801.001.201.401.601.801.38
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.72, compared to the broader market0.002.004.006.008.0010.001.72
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.08, compared to the broader market0.0010.0020.0030.0040.0050.008.08

Portfolio components
Sharpe ratioSortino ratioOmega ratioCalmar ratioMartin ratio
HROW
Harrow Health, Inc.
0.210.871.130.220.39
TMDX
TransMedics Group, Inc.
0.932.161.271.182.79
REGN
Regeneron Pharmaceuticals, Inc.
1.852.471.352.198.44
AGRX
Agile Therapeutics, Inc.
-0.85-1.990.75-0.88-1.48
NVO
Novo Nordisk A/S
2.494.021.476.6018.59
XLV
Health Care Select Sector SPDR Fund
1.241.811.221.104.04
SWAV
ShockWave Medical, Inc.
0.330.731.110.290.61
LLY
Eli Lilly and Company
3.214.521.597.7623.36

Sharpe Ratio

The current AS Sharpe ratio is 1.32. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Compared to the broad market, where average Sharpe ratios range from 1.51 to 2.35, this portfolio's current Sharpe ratio places it in the bottom 25%. This suggests that it may not be performing as well in terms of risk-adjusted returns compared to many other portfolios. The lower performance could be due to either lower returns, higher volatility, or a combination of both. This might indicate that the portfolio requires some fine-tuning. You can use the Portfolio Optimization tool to find an allocation that maximizes the Sharpe ratio.

Use the chart below to compare the Sharpe ratio of AS with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.002024FebruaryMarchAprilMayJune
1.32
2.16
AS
Benchmark (^GSPC)
Portfolio components

Dividends

Dividend yield

AS granted a 0.34% dividend yield in the last twelve months.


TTM20232022202120202019201820172016201520142013
AS0.34%0.38%0.42%0.44%0.57%0.70%0.68%0.68%0.91%0.59%0.70%0.82%
HROW
Harrow Health, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
TMDX
TransMedics Group, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
REGN
Regeneron Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
AGRX
Agile Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVO
Novo Nordisk A/S
0.69%0.71%0.84%0.94%1.33%1.51%1.97%1.52%2.87%0.92%1.43%1.23%
XLV
Health Care Select Sector SPDR Fund
1.52%1.59%1.47%1.33%1.49%2.16%1.56%1.46%1.59%1.43%1.34%1.51%
SWAV
ShockWave Medical, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.55%0.78%1.07%1.23%1.75%1.96%1.94%2.46%2.77%2.37%2.84%3.84%

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-12.00%-10.00%-8.00%-6.00%-4.00%-2.00%0.00%2024FebruaryMarchAprilMayJune0
-0.71%
AS
Benchmark (^GSPC)
Portfolio components

Worst Drawdowns

The table below displays the maximum drawdowns of the AS. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AS was 33.91%, occurring on May 11, 2022. Recovery took 219 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-33.91%Sep 3, 2021173May 11, 2022219Mar 27, 2023392
-32.11%Feb 13, 202027Mar 23, 202059Jun 16, 202086
-23.99%Jul 1, 201985Oct 29, 201922Nov 29, 2019107
-20.64%Apr 24, 2023131Oct 27, 2023110Apr 8, 2024241
-14.35%Sep 16, 202033Oct 30, 202028Dec 10, 202061

Volatility

Volatility Chart

The current AS volatility is 3.46%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%3.00%4.00%5.00%6.00%7.00%8.00%2024FebruaryMarchAprilMayJune
3.46%
2.39%
AS
Benchmark (^GSPC)
Portfolio components

Diversification

Asset Correlations Table

The table below displays the correlation coefficients between the individual components of the portfolio, the entire portfolio, and the chosen benchmark.

AGRXHROWTMDXREGNSWAVLLYNVOXLV
AGRX1.000.170.230.040.160.060.110.15
HROW0.171.000.210.130.230.140.170.22
TMDX0.230.211.000.170.360.160.190.32
REGN0.040.130.171.000.200.350.330.53
SWAV0.160.230.360.201.000.200.210.42
LLY0.060.140.160.350.201.000.450.58
NVO0.110.170.190.330.210.451.000.48
XLV0.150.220.320.530.420.580.481.00
The correlation results are calculated based on daily price changes starting from May 3, 2019